MicroRNA-29与肝纤维化  

MicroRNA-29 and Hepatic Fibrosis

作　　者：王晓丹[1,2] 石慧[1] 肖和杰[1] 张艳琼[1] 

机构地区：[1]三峡大学医学院,湖北宜昌443002 [2]湖北工业大学校医院,湖北武汉430068

出　　处：《武汉大学学报（医学版）》2014年第3期489-492,共4页Medical Journal of Wuhan University

基　　金：国家自然科学基金资助项目(编号:81200307/H0317);湖北省自然科学基金面上项目(编号:2013CFB026);湖北省卫生厅科研指导性项目(编号:JX6C-26)

摘　　要：微小RNA(microRNA,miRNAs,miR)是一类在转录后水平进行基因调控的非编码小RNA分子。miRNAs分子参与细胞生长、增殖、信号通路调控以及细胞凋亡等多个环节,与多种癌症发生发展有关。目前许多研究表明miR-29可调控多种靶基因的表达,参与多种纤维化疾病的发生、发展过程,miR-29有望成为肝纤维化基因治疗的新靶点,为阐述肝纤维化的发病机制和临床诊治提供了新思路。本文就miR-29与肝纤维化关系的研究进展做一综述。MicroRNAs are a class of small non-coding RNAs, which modulate the gene function at the post-transcriptional level and act as a fine tuner of various processes, such as development, pro- liferation, cell signaling and apoptosis. They are associated with different types and stages of cancer. Recent studies have shown that miR-29 could regulate a variety of target gene expression, and be involved in the development progress of a variety of fibrotic diseases, miR-29 is expected to become new targets of the gene therapy for hepatic fibrosis, and provides a new way for the pathogenesis, diagnosis and treatment of hepatic fibrosis. This review highlights the research progress of miR-29 in hepatic fibrosis.

关 键 词：微小RNA 肝纤维化 细胞外基质 

分 类 号：R575.2[医药卫生—消化系统]